Cullinan Associates Inc Gilead Sciences, Inc. Transaction History

Cullinan Associates Inc

$1.75 Billion
Q2 2024

A detailed history of Cullinan Associates Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Cullinan Associates Inc holds 115,332 shares of GILD stock, worth $9.64 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares

115,332

Previous 139,288 17.2%

Holding current value

$9.64 Million

Previous $10.2 Million 22.45%

% of portfolio

0.45%

Previous 0.58%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 10, 2024	SELL	$63.15 - $72.88 $1.51 Million - $1.75 Million	-23,956 Reduced 17.2%	115,332 $7.91 Million
Q1 2024 Apr 18, 2024	BUY	$71.58 - $87.29 $1.47 Million - $1.79 Million	20,532 Added 17.29%	139,288 $10.2 Million
Q4 2023 Jan 24, 2024	SELL	$73.27 - $83.09 $908,254 - $1.03 Million	-12,396 Reduced 9.45%	118,756 $9.62 Million
Q3 2023 Oct 11, 2023	SELL	$73.94 - $80.67 $16,636 - $18,150	-225 Reduced 0.17%	131,152 $9.83 Million
Q2 2023 Jul 14, 2023	BUY	$76.01 - $86.7 $208,039 - $237,297	2,737 Added 2.13%	131,377 $10.1 Million
Q1 2023 Apr 05, 2023	BUY	$77.31 - $88.08 $725,245 - $826,278	9,381 Added 7.87%	128,640 $10.7 Million
Q4 2022 Jan 11, 2023	SELL	$62.32 - $89.47 $1.93 Million - $2.77 Million	-30,923 Reduced 20.59%	119,259 $10.2 Million
Q3 2022 Oct 19, 2022	BUY	$59.54 - $68.01 $381,651 - $435,944	6,410 Added 4.46%	150,182 $9.27 Million
Q2 2022 Jul 08, 2022	BUY	$57.72 - $65.01 $590,417 - $664,987	10,229 Added 7.66%	143,772 $8.89 Million
Q1 2022 Apr 21, 2022	BUY	$57.92 - $72.58 $750,759 - $940,781	12,962 Added 10.75%	133,543 $7.94 Million
Q4 2021 Jan 07, 2022	BUY	$64.88 - $73.64 $1.5 Million - $1.7 Million	23,070 Added 23.66%	120,581 $8.76 Million
Q3 2021 Oct 08, 2021	BUY	$67.69 - $73.03 $324,235 - $349,813	4,790 Added 5.17%	97,511 $6.81 Million
Q2 2021 Jul 07, 2021	BUY	$63.47 - $69.35 $35,162 - $38,419	554 Added 0.6%	92,721 $6.39 Million
Q1 2021 Apr 20, 2021	BUY	$60.0 - $68.46 $148,080 - $168,959	2,468 Added 2.75%	92,167 $5.96 Million
Q4 2020 Jan 14, 2021	SELL	$56.65 - $64.55 $402,781 - $458,950	-7,110 Reduced 7.34%	89,699 $5.23 Million
Q3 2020 Oct 09, 2020	BUY	$62.1 - $78.08 $52,474 - $65,977	845 Added 0.88%	96,809 $6.12 Million
Q2 2020 Jul 07, 2020	BUY	$72.34 - $84.0 $42,174 - $48,972	583 Added 0.61%	95,964 $7.38 Million
Q1 2020 Apr 01, 2020	BUY	$62.63 - $80.22 $5.26 Million - $6.74 Million	83,981 Added 736.68%	95,381 $7.13 Million
Q4 2019 Jan 15, 2020	BUY	$61.62 - $67.78 $425,178 - $467,682	6,900 Added 153.33%	11,400 $741,000
Q4 2018 Jan 11, 2019	SELL	$60.54 - $79.0 $187,674 - $244,900	-3,100 Reduced 40.79%	4,500 $281,000
Q2 2018 Jul 09, 2018	SELL	$64.88 - $75.68 $223,835 - $261,096	-3,450 Reduced 31.22%	7,600 $538,000
Q1 2018 Apr 27, 2018	SELL	$72.84 - $88.8 $29,136 - $35,520	-400 Reduced 3.49%	11,050 $833,000
Q4 2017 Jan 17, 2018	BUY	$71.15 - $83.52 $14,230 - $16,704	200 Added 1.78%	11,450 $820,000
Q3 2017 Oct 16, 2017	BUY	$72.11 - $85.47 $811,237 - $961,537	11,250	11,250 $911,000

Others Institutions Holding GILD

# of Institutions

1,879

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullinan Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cullinan Associates Inc with notifications on news.

Account

Cullinan Associates Inc Gilead Sciences, Inc. Transaction History